3.40
—
Close of 6 Nov 2026, in EUR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About European Medical Solutions
Its shares trade on Euronext Brussels under the ticker ALEMS.BR. It has been listed since 11 May 2016. In the fiscal year to 31 December 2025, it reported revenue of €49.9m and net income of €1.8m. At that date it held total assets of €51.8m and shareholders' equity of €12.1m.
ASIT BioTech SA is a clinical stage biopharmaceutical company, which engages in the research and development of immunotherapy treatments for environmental and food allergies. The company is headquartered in Liege, Liege. The company went IPO on 2016-05-11.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 11 May 2016
- Employees
- 20
- Website
- asitbiotech.com/index.php ↗
Leadership
Pay as last reported
- Mr. Regis RocheChairman of the Board, since 2022
- Mr. Frank HazevoetsChief Executive Officer, Chief Financial Officer, Director, since 2020
- Mr. Gael PlacierSenior Product Development Manager
- Mr. Francois MeurgeyMarketing & Commercialization, Director
- Ms. Marie-Claire BeckersHead of Production
- Mr. Adrian CaplanusiSenior Medical Director
- Mr. Sacha GogevHead of Quality Control
- Ms. Sabine PirottonSenior Clinical Project Manager
- Mr. Albert VicaireSecretary of the company
- Mr. Michel BaijotDirector, since 2020
- Mr. Henri De MeyerDirector
- Mr. Philippe DegeerDirector - Representative of Meusinvest
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- ASIT BioTech SA develops immunotherapy treatments for environmental allergies in the Health Care sector.
- The company employs 20 full-time staff members dedicated to clinical stage biopharmaceutical research.
- European Medical Solutions SA operates as a specialized biotechnology entity focused on food allergies.
Weaknesses
- The small workforce of 20 employees may limit the scale of clinical research operations.
- Being a clinical stage company means ASIT BioTech SA has not yet generated commercial revenue.
- The limited employee count suggests potential constraints in executing large-scale development projects efficiently.
Opportunities
- Growing demand for immunotherapy solutions presents a significant market opportunity for environmental allergy treatments.
- Expanding the product portfolio to include more food allergy therapies could increase market share.
- Strategic partnerships with larger pharmaceutical firms could accelerate the development of new biopharmaceutical products.
Threats
- Intense competition from established biotechnology firms could hinder ASIT BioTech SA's market entry.
- Regulatory hurdles in the Health Care sector may delay the approval of new treatments.
- Fluctuations in funding availability could impact the ongoing research and development activities significantly.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.